1. Nephrogenic systemic fibrosis (NSF) is rare disease, occurring in patients with renal failure, which can be devastating and usually initially appears as skin thickening and hardening (Figs. 1-2 on page 2), and occasionally progressing to limb contractures leading to severe disability and even death [1] [2] [3] [4] [5] [6] [7] [8] [9] .
2. It can be very painful. The disease was first diagnosed in 1997 and first published in 2000 [10] .
3. Histologically, NSF is characterized by dermal fibrosis (Fig. 3 on page 5 ). There is always an increased number of fibrocytes that are CD34-positive (Fig. 4 on page 5 ).
4. Cutaneous or tendon fibrosis may be obaerved ( Fig. 5 on page 6 ).
The aim of this study is to review the published cases of NSF in Japan.
Images for this section: Fig. 1 : This 50-year-old Japanese man with NSF revealed an extensive thickening of the left arm. The range of motion of the fingers was severely limited and painful. 
No. of cases

Single 2
Less than double (7-15ml) 3
Not reported 4
6. Times of GBCA injection (n=9).
No. of cases
Single 2
Multiple 6
Not reported 1 7. Dialysis status or CKD stage.
No. of cases
Peritoneal dialysis 4
Peritoneal and hemodialysis 1 Hemodialysis 7
CKD4 without dialysis 1 CKD3 at injection, and CKD4 at onset 1
Not reported 1 8. GBCA administration even after onset of NSF
No. of cases
Yes 3
No or unknown 12
Conclusion
The literature search could reveal only 15 biopsy-verified NSF cases in Japan.
1) In Japan, gadodiamide is not approved higher doses than 0.1mmol/kg body weight. Double dose administration has been allowed for the very limited indications.
2) Japanese physicians may have a limited knowledge about NSF. Patients with nonsevere diseases may have been overlooked. In the most of NSF patients primary symptoms appeared in the lower extremities. Non-disabling lesions on the lower extremities may easily be overlooked. 1) In our study, all 8 patients (GBCA specified) had gadodiamide (Omniscan®) before developing NSF. In Japan, market share of Omniscan is around 30%, 50% for Magnevist, and 10% of ProHance (data obtained from three vendors in Japan).
Suggested risk factors of
2) In 5 patients, the amount of GBCA was single (n=2) or less than double (n=3).
3) 5 of 9 patients with documented GBCA exposure underwent peritoneal dialysis when GBCA was administered. In Japan, only 3.4% of 275,000 patients under treatment with dialysis undergo peritoneal dialysis [36] .
4) In 2 patients, no dialysis was performed:
CKD4 without dialysis.
CKD3 at injection, and CKD4 at onset.
NSF is found among Japanese end-stage renal failure patients even after single dose examinations, and even in a patient with CKD3 at GBCA exposure. 
